



These additions apply to Exchange formularies and are effective 10/13/23

Additions:

Leqembi (lecanemab-irmb) – Medical benefit, PA

Aduhelm (aducanumab) – Medical benefit, PA

Elfabrio (pegunigalsidase alfa-iwxj) – Medical benefit, post service claims edit

Skyclarys (omaveloxolone) – Pharmacy benefit, Non-Preferred brand, PA and QL of 3 per day

Vowst (fecal microbiota spores, live brpk) – Pharmacy benefit, Non-Preferred brand, PA and QL of 12 per 3 days

Joenja (leniolisib) – Pharmacy benefit, Non-Preferred brand, PA and QL of 2 per day

Daybue (trofinetide) – Pharmacy benefit, Non-Preferred brand, PA and QL of 120ml per day

Epkinly (epcoritamab-bysp) – Medical benefit, PA

Columvi (glofitamab-gxbm) – Medical benefit, PA

Abilify Asimtufii (aripiprazole) – Medical benefit

Adlarity (donepezil patch) – Pharmacy benefit, Non-Preferred brand, PA and QL of 4 per 28 days

Aspruzyo (ranolazine sprinkle) – Pharmacy benefit, Non-Preferred brand, PA and QL of 2 per day

Epsolay (benzoyl peroxide) – Pharmacy benefit, Non-Formulary

Changes:

Vraylar (cariprazine) – Pharmacy Benefit, update to PA criteria, add major depressive disorder indication

Kalydeco (ivacaftor) – Pharmacy Benefit, update to PA criteria, remove age

Linzess (linaclotide) – Pharmacy Benefit, update to PA criteria, age update